- Home
- CGNT vs GRAL Comparison
CGNT vs GRAL Comparison
Compare CGNT & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- GRAL
- Stock Information
- Founded
- CGNT 2020
- GRAL 2016
- Country
- CGNT Israel
- GRAL United States
- Employees
- CGNT N/A
- GRAL N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- GRAL
- Sector
- CGNT Technology
- GRAL
- Exchange
- CGNT Nasdaq
- GRAL NYSE
- Market Cap
- CGNT 649.9M
- GRAL 610.9M
- IPO Year
- CGNT N/A
- GRAL N/A
- Fundamental
- Price
- CGNT $9.53
- GRAL $27.78
- Analyst Decision
- CGNT Hold
- GRAL Hold
- Analyst Count
- CGNT 3
- GRAL 2
- Target Price
- CGNT $8.25
- GRAL $16.00
- AVG Volume (30 Days)
- CGNT 274.7K
- GRAL 1.1M
- Earning Date
- CGNT 12-11-2024
- GRAL 02-15-2025
- Dividend Yield
- CGNT N/A
- GRAL N/A
- EPS Growth
- CGNT N/A
- GRAL N/A
- EPS
- CGNT N/A
- GRAL N/A
- Revenue
- CGNT $339,818,000.00
- GRAL $117,669,000.00
- Revenue This Year
- CGNT $13.67
- GRAL $32.48
- Revenue Next Year
- CGNT $6.92
- GRAL $14.72
- P/E Ratio
- CGNT N/A
- GRAL N/A
- Revenue Growth
- CGNT 12.16
- GRAL 111.83
- 52 Week Low
- CGNT $6.21
- GRAL $12.33
- 52 Week High
- CGNT $9.97
- GRAL $32.65
- Technical
- Relative Strength Index (RSI)
- CGNT 58.56
- GRAL N/A
- Support Level
- CGNT $8.92
- GRAL N/A
- Resistance Level
- CGNT $9.55
- GRAL N/A
- Average True Range (ATR)
- CGNT 0.41
- GRAL 0.00
- MACD
- CGNT -0.03
- GRAL 0.00
- Stochastic Oscillator
- CGNT 61.87
- GRAL 0.00
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.